Business StandardCenter·
US FDA flags blindness risk from GLP-1 drugs: What patients should know
The US regulator has called for new eye-related warnings on GLP-1 drug labels, but Indian safety data remains limited
Read at Business Standard →
Business · 1 sources covering this
US FDA flags blindness risk from GLP-1 drugs: What patients should know
The US regulator has called for new eye-related warnings on GLP-1 drug labels, but Indian safety data remains limited
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://hindustansphere.com/embed/cluster/2cd2b8b08d51a96bc37bfcd364cd59269002310a" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="US FDA flags blindness risk from GLP-1 drugs: What patients should know"></iframe>
